[{"orgOrder":0,"company":"Mogrify","sponsor":"Astellas Venture Management","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"Mogrify \/ Astellas Venture Management","highestDevelopmentStatusID":"4","companyTruncated":"Mogrify \/ Astellas Venture Management"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Negev Labs","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Negev Labs","highestDevelopmentStatusID":"4","companyTruncated":"Beckley Psytech \/ Negev Labs"},{"orgOrder":0,"company":"Complement Therapeutics","sponsor":"Gimv","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Complement Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Complement Therapeutics \/ Gimv","highestDevelopmentStatusID":"4","companyTruncated":"Complement Therapeutics \/ Gimv"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"PAS-nomacopan","moa":"Leukotriene B4","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Akari Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The acquisition of Beckley Psytech's Ophthalmology development program aligns with Negev's mission to develop the full therapeutic potential of neuroplastogens.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 11, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Negev Labs

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 (LTB4) product candidate for intravitreal treatment of geographic atrophy (GA).

                          Product Name : Coversin

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 19, 2024

                          Lead Product(s) : Nomacopan

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : With the financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geograpic Atrophy (GA) secondary to dry age-related ma...

                          Product Name : CTX001

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 17, 2023

                          Lead Product(s) : Exagamglogene Autotemcel

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Gimv

                          Deal Size : $78.9 million

                          Deal Type : Series A Financing

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : rVA576 (nomacopan) is a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) in clinical development for pediatric and adult HSCT-TMA.

                          Product Name : Coversin

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 15, 2023

                          Lead Product(s) : Nomacopan

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Astellas Venture Management

                          Deal Size : $46.0 million

                          Deal Type : Series A Financing

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          August 30, 2022

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : AmbioPharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The new data showing extended dose intervals, together with data previously presented, showing LTB4 inhibition by PAS-nomacopan may also reduce risk of sight-threatening CNV, suggest PAS-rVA576(nomacopan) may be a potential novel and effective treatment ...

                          Product Name : Coversin

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 28, 2022

                          Lead Product(s) : Nomacopan

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OKYO intends to use the net proceeds from this Offering: (i) to advance OK-101 to the filing of an IND to treat DED; (ii) to fund the initial Phase 2 clinical trial of OK-101 in DED patients; and (iii) for working capital and other general corporate purp...

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 19, 2022

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Thinkequity

                          Deal Size : $2.5 million

                          Deal Type : Public Offering

                          blank

                          09

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OKYO Pharma intends to use the net proceeds of the offering to advance OK-101 to the filing of an IND to treat DED, to fund the initial Phase 2 clinical trial of OK-101 in DED patients, and the remaining proceeds for working capital and other general cor...

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 16, 2022

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Thinkequity

                          Deal Size : $2.5 million

                          Deal Type : Public Offering

                          blank

                          10

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : OK101, lead pre-clinical compound and a novel long-acting GPCR-based anti-inflammatory drug candidate, company issues US Patent that covers key claim information of OK101 useful in treatment of dry eye disease.

                          Product Name : OK-101

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 14, 2021

                          Lead Product(s) : Urcosimod

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank